Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Peter MacCallum Cancer Centre · University of Melbourne · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
191
total citations
- FWCI
- 46.22
- Percentile
- 100%
- References
- 16
Citations per year
Authors
62- MSMichael S. HofmanCorresponding
Peter MacCallum Cancer Centre, University of Melbourne
- LELouise Emmett
St Vincent's Hospital Sydney, UNSW Sydney
- SSShahneen Sandhu
University of Melbourne, Peter MacCallum Cancer Centre
- AIAmir Iravani
Peter MacCallum Cancer Centre
- JPJames P Buteau
University of Melbourne, Peter MacCallum Cancer Centre
Topics & keywords
Topics
Keywords
- Cabazitaxel
- Prostate cancer
- Medicine
- Open label
- Oncology
- Overall survival
- Internal medicine
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- PCProstate Cancer Foundation
- NNovartis
- ANAustralian Nuclear Science and Technology OrganisationAward: CAN4CANCER
- MFMovember Foundation
- AGAustralian Government
- CACancer Australia
- UOUniversity of Sydney
- PMPeter MacCallum Foundation
- AAAustralian and New Zealand Urogenital and Prostate Cancer Trials Group
- NHNational Health and Medical Research Council